Drug Class Detail

Drug Class MET Antibody

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ME22S EGFR Antibody 27 MET Antibody 13 ME22S is a bispecific antibody that targets EGFR and MET, which results in decreased tumor cell proliferation and migration (PMID: 26812910).
SYM015 MET Antibody 13 Sym015 is a mixture of two antibodies that bind to MET, leading to MET degradation and decreased growth of MET-dependent tumor cells (Cancer Res July 15 2016 (76) (14 Supplement) 1219).
LY3164530 EGFR Antibody 27 MET Antibody 13 LY3164530 is a bispecific antibody that targets EGFR and c-Met and inhibits activation of downstream signaling, resulting in decreased proliferation of EGFR and c-Met over expressing tumor cells (NCI Drug Dictionary).
EMB-01 EMB01|FIT-013a EGFR Antibody 27 MET Antibody 13 Limited information is currently available on EMB-01, a putative bispecific antibody against EGFR and cMET (Feb, 2019).
Emibetuzumab LY2875358 MET Antibody 13 MET Inhibitor 50 Emibetuzumab (LY2875358) is MET-targeted antibody, which inhibits binding of the MET ligand HGF and promotes internalization and downregulation of MET, resulting in decreased HGF-dependent and HGF-independent signaling and potentially leading to decreased growth of MET-expressing tumors (PMID: 27803065, PMID: 25231402).
ARGX-111 MET Antibody 13 ARGX-111 is a monoclonal antibody that binds to c-MET, resulting in inhibition of downstream signaling and decreased proliferation of c-MET expressing tumor cells (NCI Drug Dictionary).
JNJ-61186372 EGFR Antibody 27 MET Antibody 13 JNJ-61186372 is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193).
KTN0073-IgG2 MET Antibody 13 MET Inhibitor 50 KTN0073-IgG2 is a MET targeted antibody engineered to an IgG2 isotype, which inhibits ligand binding and induces degradation of both wild-type and mutant forms of MET, resulting in decreased tumor cell proliferation, including tumor cells harboring MET mutations and/or amplification (PMID: 27550450).
KTN0073-IgG1 MET Antibody 13 MET Inhibitor 50 KTN0073-IgG1 is a chimeric anti-MET antibody comprised of a rodent variable region and human IgG1 region, which inhibits phosphorylation of MET and induces MET degradation, potentially resulting in decreased proliferation of tumor cells harboring wild-type or mutant MET (PMID: 27550450).
ABT-700 h224G11 MET Antibody 13 ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362).
Telisotuzumab vedotin ABBV-399|Teliso-V MET Antibody 13 Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET expressing tumor cells, resulting in cell death (PMID: 27573171).
Onartuzumab MetMAb|RO5490258 MET Antibody 13 Onartuzumab is a monovalent antibody that binds MET and inhibits MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23882082).
SAIT301 MET Antibody 13 SAIT301 is a monoclonal antibody that targets SAIT301, resulting in decreased downstream signaling and potentially leading to decreased tumor cell proliferation (PMID: 24722284).